Novo Holdings’ $16.5 billion planned acquisition of Catalent is facing another delay. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process.
Tie-ups of candy makers and nutritional product companies into a single firm called Bettera has culminated in a $1 billion acquisition by Catalent. The global contract manufacturing giant plans to leverage Bettera’s ability to produce gummies and chewables as a way to offer its customers new formulation options for nutraceutical products.
Monica Vajani, Executive Director for mHUB’s MedTech Accelerator, discusses how mHUB is helping innovators transition healthcare towards value-based care.
The deal follows by weeks Thermo Fisher's acquisition, for $1.7 billion, of gene therapy contract manufacturing organization Brammer Bio.